Loading...

Dog Cancer Treatment Gets Green Light from FDA

July 21, 2021 by Daniel Mollenkamp
Dog Cancer Treatment Gets Green Light from FDA

WASHINGTON – Dog-owners whose pets are diagnosed with a common form of cancer now have a federally approved treatment option. 

That new treatment, the first fully approved drug for canine lymphoma, has shown the conditional track of animal medicine can fulfill its mission to greenlight treatments for rare animal diseases, according to the U.S. Food and Drug Administration. 

The FDA gave the first full approval last week to a treatment for lymphoma in dogs. The treatment, Tanovea (rabacfosadine injection), is the first new animal drug available under conditional approval to become fully approved, according to materials from the agency.

The company associated with the newly approved drug, VetDC, Inc., has claimed that Tanovea has “demonstrated a 77% overall response and a 45% complete response rate, supporting a reasonable expectation of efficacy in both naïve and relapsed/refractory lymphoma.” 

Another company, Elanco Animal Health, will be the exclusive distributor of TANOVEA-CA1, after a development and commercialization agreement with VetDC.

Tanovea had already received “conditional approval” under an FDA program for animal treatments in 2016. 

Conditional approval is a designation that lets drug companies sell pet medicine that hasn’t yet been proven to meet the FDA’s full requirements for diseases, which is allowed under 2004 Congressional legislation. That 2004 legislation, the Minor Use and Minor Species Animal Health Act, was meant to make medicine available to pets that don’t have a lot of options, according to the FDA. 

It had tried to accomplish this by increasing the amount of legally approved medicine for minor species, such as ferrets and fish, and for minor uses in major species, like treating cancer in dogs, the FDA has said. In both cases, it wanted to make drugs that there wasn’t much of a financial incentive to pursue, easier to bring to market. It was expanded in 2018 to include more drugs in the conditional pathway, which the agency has said is a “main provision” of the law. 

The legislation was also created to eliminate the “financial roadblocks” pharmaceutical companies face in trying to bring “limited-demand animal drugs” to the market, the FDA said.

Globally, the animal medicines market has grown consistently since 2015 and has been projected to keep growing as well, with especially pronounced growth in the U.S.

Lymphoma is considered a disease of the immune system that grows in “lymphocytes,” a kind of white blood cell, the FDA said. It can affect any organ in the body, but it is most common in organs attached to the function of the immune system, according to written materials from the agency. The symptoms of the disease for dogs vary, and its causes are not presently known. 

According to the American Kennel Club, lymphoma is a common cancer in dogs and is similar to the disease in humans. The same chemotherapy protocols can be used in both humans and dogs. A spokesperson for the FDA has said that lymphoma represents as much as 24% of all cancer in dogs.

While a significant and relatively common form of canine cancer, it still only affects about 70,000 dogs a year, according to materials from the FDA. For context, the American Veterinary Medical Association estimates that there are more than 48 million households in the U.S. that own dogs, almost 40% of the population, making up a total of just shy of 77 million pet dogs in the country.

The FDA touts the approval as a vindication of its conditional pathway.

“This gives veterinarians another important tool to help extend the quality of life for dogs with lymphoma, and potentially give them and their owners more time together,” said Steven M. Solomon, director of the FDA’s Center for Veterinary Medicine.

The FDA has indicated that it hopes to use the pathway more in the near future.

“We’re committed to continue using all our authorities to help make limited-demand treatment options available to our animal companions,” Acting FDA Commissioner Janet Woodcock said. 

In The News

Health

Voting

Regulation

Federal Appeals Court Stays FDA Ban on Juul E-Cigarettes

WASHINGTON — A federal appeals court on Friday stayed the Food and Drug Administration's ban on sales of Juul Labs... Read More

WASHINGTON — A federal appeals court on Friday stayed the Food and Drug Administration's ban on sales of Juul Labs Inc's e-cigarettes, after the company appealed the agency's order on the grounds the ban would cause it "irreparable harm." The U.S. Circuit Court of Appeals for... Read More

June 23, 2022
by Eden Metzger
FDA Says No to Juul Sales

WASHINGTON — The Food and Drug Administration on Thursday ordered Juul Labs to pull its electronic cigarettes from the U.S.... Read More

WASHINGTON — The Food and Drug Administration on Thursday ordered Juul Labs to pull its electronic cigarettes from the U.S. market, a move intended to curb a multibillion-dollar industry blamed for sparking a national surge in teen vaping.  "Today's action is further progress on the FDA's... Read More

June 21, 2022
by Dan McCue
Business Groups Pushing Back Hard on SEC Emissions Reporting Proposal

WASHINGTON — Business groups and corporate lobbyists were among those pushing back hardest as the deadline elapsed Friday on a... Read More

WASHINGTON — Business groups and corporate lobbyists were among those pushing back hardest as the deadline elapsed Friday on a Securities and Exchange Commission proposal that would require companies for the first time to disclose their carbon emissions and climate change risks to investors. In March,... Read More

June 19, 2022
by Dan McCue
Verizon, AT&T Agree to Delay Some of 5G Deployment Until Mid-2023

WASHINGTON — Verizon Communications and AT&T have voluntarily agreed to delay some deployment of their long-awaited C-band 5G usage until... Read More

WASHINGTON — Verizon Communications and AT&T have voluntarily agreed to delay some deployment of their long-awaited C-band 5G usage until July 2023 as air carriers continue to work to retrofit passenger and cargo aircraft to ensure they do not encounter instrument interference from the rollout. As... Read More

June 17, 2022
by Dan McCue
Feds Unveil Plan to Get Clean Energy on the Grid Faster

WASHINGTON — Federal regulators on Thursday rolled out a proposed overhaul of long-standing policies governing how new power projects are... Read More

WASHINGTON — Federal regulators on Thursday rolled out a proposed overhaul of long-standing policies governing how new power projects are connected to transmission lines. The intention behind the proposal from the Federal Energy Regulatory Commission is to unstop a bottleneck of renewable and other clean energy... Read More

June 17, 2022
by Dan McCue
FDA Approves COVID Vaccines for Children Aged 5 and Younger

WASHINGTON — The Food and Drug Administration on Friday gave its approval for COVID-19 vaccines for children age 5 and... Read More

WASHINGTON — The Food and Drug Administration on Friday gave its approval for COVID-19 vaccines for children age 5 and younger.  The shots could start as early as next week if, as expected, the Centers for Disease Control and Prevention agrees with the FDA assessment. In... Read More

News From The Well